-
Gilead Seeks Full FDA Approval Of Its Remdesivir Drug For Coronavirus
Tuesday, August 11, 2020 - 1:34am | 410Read More...Gilead Sciences, Inc (NASDAQ: GILD) announced Monday it was seeking complete Food and Drug Administration approval for its drug Remdesivir, which is being used in the treatment of COVID-19. What Happened The drugmaker said it has filed a New Drug Application with the FDA on the basis of...
-
Pfizer, Gilead Strike Multiyear Partnership To Manufacture COVID-19 Drug Remdesivir
Friday, August 7, 2020 - 10:07am | 414Read More...Large-cap biopharma companies Pfizer Inc. (NYSE: PFE) and Gilead Sciences, Inc. (NASDAQ: GILD) announced a deal Friday for GIlead's remdesivir, which has been accorded emergency use authorization by the FDA for treating COVID-19. The Pfizer-Gilead Partnership: Pfizer said it has entered a...
-
Gilead Analysts Downplay Q2 Miss Amid Remdesivir's COVID-19 Opportunity
Friday, July 31, 2020 - 12:56pm | 824Read More...Gilead Sciences, Inc. (NASDAQ: GILD) reported second-quarter revenues and earnings that trailed expectations. The Gilead Analysts Morgan Stanley analyst Matthew Harrison maintained an Equal-Weight rating and $79 price target for Gilead. Raymond James analyst Steven Seedhouse maintained a Market...
-
Ex-FDA Commissioner Gottlieb On Whether Coronavirus Vaccine Will Bring Return To Normal
Monday, July 27, 2020 - 10:54am | 368Read More...Many investors are working under the assumption that a safe vaccine against the coronavirus will allow society to return to how it was pre-pandemic. Investors may be missing part of the story, including how the vaccines work, former FDA Commissioner Dr. Scott Gottlieb said on CNBC's "...
-
Credit Suisse Upgrades Gilead On Remdesivir Commercial Opportunity
Monday, July 20, 2020 - 11:38am | 780Read More...The biotech sector is a surefire winner due to a two-pronged benefit from the coronavirus pandemic, according to an analyst at Credit Suisse. Biotechs To Outperform In Q2? The biotech sector is not only the likely source of the solution to the pandemicm but is also fairly...
-
BofA On 3 Coronavirus Vaccine Frontrunners, The Remdesivir Opportunity And Antibodies
Friday, July 17, 2020 - 12:47pm | 792Read More...The markets are ready for a steady flow of updates from COVID-19 drug and vaccine developers as the world races to contain the pandemic and bring back some semblance of normalcy. Against this backdrp, BofA Securities issued an update to its view on COVID-19 market opportunities. Mixed Results...
-
Gilead's Remdesivir Data Shows Improved Clinical Recovery, Reduced Death Rate
Friday, July 10, 2020 - 10:05am | 276Read More...Gilead Sciences, Inc. (NASDAQ: GILD) shares are seeing some upward momentum following the biopharma's announcement of additional data on its COVID-19 treatment candidate remdesivir. What Happened: Gilead said a comparative analysis of the Phase 3 SIMPLE-Severe trial and a real-world...
-
Gilead Announces Pricing Of Coronavirus Treatment Remdesivir: 'We Believe All Patients Will Have Access'
Monday, June 29, 2020 - 9:38am | 638Read More...Gilead Sciences, Inc. (NASDAQ: GILD) announced pricing Monday for its antiviral remdesivir, which has been granted emergency use authorization by the FDA for treating COVID-19. The Price Of Remdesivir: The biopharma has set a price of $390 per vial for the governments of developed...
-
FDA Withdraws Emergency Use Authorization For Hydroxychloroquine
Tuesday, June 16, 2020 - 5:07am | 233Read More...The United States Food and Drug Administration on Monday withdrew the emergency use authorization it granted for hydroxychloroquine and chloroquine sulfates against the COVID-19 coronavirus. The federal agency had granted the EUA for the antimalarial drugs in late March based on preliminary studies...
-
Here's How Large Option Traders Are Playing Gilead Following Latest COVID-19 Trial Data
Thursday, June 11, 2020 - 2:00pm | 722Read More...Shares of Gilead Sciences, Inc. (NASDAQ: GILD) traded lower by 4% on Thursday amid broad market weakness following a spike in U.S. coronavirus cases. Gilead’s remdesivir is one of the most advanced potential treatments for COVID-19, but several options traders made large bets on Thursday that...
-
Gilead Analyst: Coronavirus Drug, Arcus Collaboration Make Biopharma A Buy
Wednesday, June 3, 2020 - 11:20am | 354Read More...The consensus estimates for Gilead Sciences, Inc. (NASDAQ: GILD) appear overly conservative, especially given the prospects of remdesivir and products from the company’s recent collaboration with Arcus Biosciences Inc (NYSE: RCUS), according to Leerink. The Gilead Sciences Analyst Geoffrey...
-
Pharma Large And Mid-Caps Race Against COVID-19
Tuesday, June 2, 2020 - 2:50pm | 638Read More...COVID-19 coronavirus made us realize that health should always be our top priority. Here are some companies working to make the world a better place after the pandemic. AbbVie Inc – Botox To The Rescue With unappreciated potential, the stock of this big drugmaker has stellar...
-
Gilead Falls On Mixed Results From Late-Stage Remdesivir Study In Moderate COVID-19
Monday, June 1, 2020 - 11:14am | 412Read More...Gilead Sciences, Inc. (NASDAQ: GILD) shares have come under selling pressure after the company released results Monday from a Phase 3 study of its COVID-19 treatment candidate remdesivir. Gilead's Mixed Remdesivir Data The company announced topline results from the Phase 3 SIMPLE study in...
-
UK Clears Gilead's Remdesivir For Some Coronavirus Patients
Tuesday, May 26, 2020 - 3:46pm | 350Read More...The U.K. approved the use Tuesday of Gilead Sciences Inc's (NASDAQ: GILD) remdesivir for some patients with COVID-19. The drug is to be made available on the NHS for some patients. U.K. Health Minister Matt Hancock says the antiviral drug is probably the biggest step forward...
-
Gilead Works To 'Maximize Global Supply' Of Coronavirus Candidate Remdesivir Amid Threat Of Patent Loss
Wednesday, May 6, 2020 - 10:49am | 616Read More...Gilead Sciences, Inc. (NASDAQ: GILD) recently received emergency use authorization from the FDA for its coronavirus treatment candidate remdesivir. The company now faces a conundrum: either mass produce the drug to satisfy the rising global demand or license the drug to others,...
